Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal irinotecan (II) combination vs nab-paclitaxel + gemcitabine for first-line metastatic pancreatic cancer
ChiCTR2500113348Phase 3Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Nov 2025
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of irinotecan liposome injection in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Overall Survival. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
irinotecan liposome injection
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2500113348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113348.